Details:
GSK, has discontinued its Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody, GSK2831781 (IMP731), in patients with active ulcerative colitis. The collaboration remains in place and GSK2831781 continues to be under an exclusive license with GSK.
Lead Product(s): IMP731
Therapeutic Area: Gastroenterology Product Name: GSK2831781
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 22, 2021